03692.HK
Hansoh Pharmaceutical Group Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 32.36
−2.18%Oct 27, 2026, 08:12 UTC
Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. falling 4.6% and China Construction Bank, CK Infrastructure and H&H International Holdings reaching record highs.
Source:Oct 27, 2026, 04:12 UTC
Hong Kong-listed shares showed varied moves at midday, including Xiaomi Corp. down 4.2%, Lenovo Group Ltd. up 5.8%, and Duality Biotherapeutics, Inc. down 29.4%.
Source:Oct 23, 2026, 08:58 UTC
Hansoh Pharmaceutical Group Co., Ltd. signed a strategic cooperation agreement with the China Science and Technology Development Foundation and pledged a donation of 100 million yuan for public-interest projects.
Source:Oct 23, 2026, 04:12 UTC
Hong Kong-listed shares showed mixed moves at the half-day close, with Xiaomi Corp. up 5% to HK$27.10, China Construction Bank up 1.9% to HK$9.90, Tencent Holdings Ltd. down 0.5% to HK$380.60, Alibaba down 0.5% to HK$96.90, and other named constituents and mid- and small-cap stocks moving as reported.
Source:Oct 22, 2026, 04:12 UTC
Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.
Oct 20, 2026, 08:12 UTC
Hong Kong-listed shares had mixed moves, including Alibaba down 3.6% and Lenovo Group Ltd. down 10%, while Hansoh Pharmaceutical rose 8.3%; Luxxu Group Ltd. and Chervon Holdings Ltd. reached record highs.
Source:Oct 20, 2026, 04:12 UTC
Hong Kong stocks fell in the half-day session, with the Hang Seng Index down 1.0% to 23,956, the Hang Seng Tech Index down 1.2% to 4,058, and the Hang Seng China Enterprises Index down 0.9% to 8,055.
Source:Oct 20, 2026, 02:17 UTC
Hansoh Pharmaceutical Group Co., Ltd. shares rose 6.36% to HK$33.76, after opening 2.71% higher and reaching HK$34.38.
Source:Oct 19, 2026, 10:14 UTC
Hansoh Pharmaceutical and its wholly owned subsidiary Hansoh Pharmaceutical Group Co., Ltd. entered into a strategic collaboration and license agreement with F. Hoffmann-La Roche AG covering multiple antibody-drug conjugate programs.
Oct 11, 2026, 10:34 UTC
The EUROPEAN MEDICINES AGENCY accepted Hansoh Pharmaceutical Group Co., Ltd.’s resubmitted EU marketing authorisation application for almonertinib on October 7, 2026, and began the centralised review process for the specified advanced NSCLC indications.
Oct 2, 2026, 04:12 UTC
Hong Kong stocks fell in the morning session on October 2, 2026, with the Hang Seng Index down 648 points (2.6%) to 23,964 and the Hang Seng Tech Index down 104 points (2.4%) to 4,149, while Central New Energy hit a record high, up 10.5%.
Sep 30, 2026, 08:12 UTC
Hong Kong stocks closed higher on September 30, 2026, with the Hang Seng Index up 89 points or 0.4% at 24,613 and the Hang Seng Tech Index up 4 points or 0.1% at 4,253, on turnover of HK$187.158 billion.
Sep 30, 2026, 04:12 UTC
Hong Kong stock indices closed the morning session mixed, with the Hang Seng Index down 10 points at 24,513 and the Hang Seng Tech Index down 6 points at 4,243, while CSPC Pharmaceutical rose over 5% and GenScript Biotech hit a new high.
Source:Sep 28, 2026, 02:18 UTC
Hansoh Pharmaceutical Group announced plans to resubmit its marketing application for Aumseqa (almonertinib) to the European Medicines Agency based on the original data package as soon as possible.
Source:Sep 27, 2026, 10:55 UTC
The European Commission issued an implementing decision on September 25, 2026 formally revoking the EU marketing authorization for Hansoh Pharmaceutical's innovative drug Aumseqa (aumolertinib) as monotherapy.
Source:Sep 25, 2026, 02:44 UTC
China's National Medical Products Administration accepted Hansoh Pharmaceutical's marketing application for its self-developed HS-20093 (recombinant anti-B7-H3 antibody-drug conjugate) injection for the treatment of osteosarcoma in patients aged 12 or older who failed at least two prior lines of therapy.
Source:Sep 24, 2026, 08:11 UTC
Hansoh Pharmaceutical reported that its first-half revenue rose 12% year on year, with net profit up 36% year on year.
Source:Sep 24, 2026, 04:12 UTC
Hong Kong stocks fell in the morning session on September 24, 2026, with the Hang Seng Index down 129 points to 24,704 and the Hang Seng Tech Index down 48 points to 4,330.
Sep 24, 2026, 00:18 UTC
At the 2026 WCLC in Seoul, Chinese innovative oncology drugs were presented, including Akeso's ivonescimab showing superior head-to-head results over pembrolizumab in first-line NSCLC, and Hansoh/Yilian B7-H3 ADC entering the plenary session.
Source:Sep 22, 2026, 09:13 UTC
Hansoh Pharmaceutical announced that its injectable HS-20093 (riconvilutamab) for the treatment of osteosarcoma in patients aged 12 and older who failed at least two prior lines of therapy was included in China's National Medical Products Administration priority review and approval procedure.
Source:Sep 20, 2026, 23:45 UTC
Hansoh Pharmaceutical announced that its self-developed TYK2 selective allosteric inhibitor HS-10374 met the co-primary endpoints in a pivotal Phase III clinical trial for adults with moderate-to-severe plaque psoriasis.
Source:Sep 16, 2026, 09:03 UTC
Hansoh Pharmaceutical Group announced that its self-developed Class 1 new drug HS-20197 for injection received a drug clinical trial approval notice from China's National Medical Products Administration (NMPA) for clinical trials in advanced solid tumors.
Source:Sep 14, 2026, 08:55 UTC
China Resources Double-Crane's wholly owned subsidiary China Resources Saike received drug registration certificates from the National Medical Products Administration for Ezetimibe and Atorvastatin Calcium Tablets (I) and (II), approved for market on September 8, 2026.
Source:Sep 8, 2026, 04:06 UTC
Sinopharm Group and Hansoh Pharmaceutical reached a strategic cooperation agreement, covering broad market, medical access, retail, and DTP special cooperation agreements, upgrading their collaboration to full-chain, full-cycle strategic coordination.
Source:Aug 26, 2026, 09:34 UTC
Hansoh Pharmaceutical declared an interim dividend of 28.5 HK cents per share for H1 2026, up about 23% from 23.16 HK cents in the prior-year period.
Source:Aug 26, 2026, 09:32 UTC
Hansoh Pharmaceutical announced its first-half 2026 results, with revenue of approximately 8.304 billion RMB, up 11.7% year-on-year, and profit of approximately 4.258 billion RMB, up 35.8% year-on-year.
Jul 23, 2026, 03:07 UTC
Chongqing Pharmaceutical Holding and Hansoh Pharmaceutical Group officially launched the Xinfengyi project strategic partnership, covering 9 provinces and municipalities, to integrate resources and deepen collaboration in market access and emerging businesses.
Source: